


## TSPO ligand-1

## Chemical Properties

|                   |  |
|-------------------|--|
| CAS No. :         | 4560-08-1  |
| Formula:          | C <sub>16</sub> H <sub>10</sub> ClNO <sub>2</sub>  |
| Molecular Weight: | 283.71   |
| Storage:          | Store at low temperature<br>Powder: -20°C for 3 years   In solvent: -80°C for 1 year<br><i>Actual storage temperature shall be subject to the COA.</i> |



## Biological Description

|               |   |
|---------------|---|
| Description   | TSPO ligand-1 has affinity for peripheral and central benzodiazepine receptors. TSPO ligand-1 is an AUTAC4-binding protein in the transmembrane domain of the outer mitochondrial membrane, which induces mitochondrial autophagy and promotes intracellular mitochondrial regeneration. TSPO ligand-1 is involved in intracellular cholesterol transport, and can be used as a biomarker for brain injury and neurodegeneration. TSPO ligand-1 is involved in intracellular cholesterol transport and can be used as a biomarker for brain damage and neurodegeneration.                 |
| Targets(IC50) | Autophagy, Ligands for Target Protein for PROTAC  |
| In vitro      | In the context of selective activation of neurons in male C57Bl6/N mice, the TSPO ligand-1 gene is induced to increase expression. Additionally, under both physiological and psychopharmacological conditions, neuronal activation leads to increased TSPO levels in adult mice[2].<br>As the sole marker of glial cell activity in Alzheimer's disease, TSPO ligand-1 can track the formation of different neural cells[4].<br>In the MA-10 Leydig cell line, TSPO ligand-1 can regulate mitochondrial fatty acid oxidation (FAO) and thus affects mitochondrial energy homeostasis[3]. |

## Solubility Information

|                     |   |
|---------------------|---|
| Solubility          | DMSO: 50 mg/mL (176.24 mM), Sonication is recommended.<br>( < 1 mg/ml refers to the product slightly soluble or insoluble)  |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.05 mM), Sonication is recommended.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

### Preparing Stock Solutions

---

|       | 1mg       | 5mg        | 10mg       |
|-------|-----------|------------|------------|
| 1 mM  | 3.5247 mL | 17.6236 mL | 35.2473 mL |
| 5 mM  | 0.7049 mL | 3.5247 mL  | 7.0495 mL  |
| 10 mM | 0.3525 mL | 1.7624 mL  | 3.5247 mL  |
| 50 mM | 0.0705 mL | 0.3525 mL  | 0.7049 mL  |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Takahashi D, et al. AUTACs: Cargo-Specific Degradable Using Selective Autophagy. *Mol Cell*. 2019 Dec 5;76(5):797-810.e10.

Tina Notter, et al. Neuronal activity increases translocator protein (TSPO) levels. *Mol Psychiatry*. 2021 Jun;26(6):2025-2037.

Lan N Tu, et al. Translocator Protein (TSPO) Affects Mitochondrial Fatty Acid Oxidation in Steroidogenic Cells. *Endocrinology*. 2016 Mar;157(3):1110-21.

Benjamin B Tournier, et al. Astrocytic TSPO Upregulation Appears Before Microglial TSPO in Alzheimer's Disease. *J Alzheimers Dis*. 2020;77(3):1043-1056.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481